GHP Funds

SVP I

SVP I, the debut fund for the firm, closed in December 2002 and invested with four highly successful leveraged buyout funds. SVP I is diversified by sector and geography.

Learn More
SVP II

SVP II is a leveraged buyout fund of funds which closed in December 2006. SVP II represents a continuation of the successful strategy utilized by the predecessor fund, primarily investing with large, top tier LBO and growth equity firms. SVP II is diversified by sector and geography.

Learn More
SVP RE I

SVP Real Estate I, LP ("SVP RE I"), closed in February 2008, is a private real estate fund of funds. As with SVP I & II, SVP RE I received allocations with historically successful, highly sought after underlying fund managers who pursue compelling investment strategies. The fund is diversified by sector (Office, Hotel, Industrial/Warehouse, Retail and Residential) and geography (U.S., Europe, and Asia/Pacific).

Learn More
GHP COF

The GHP Credit Opportunity Fund (“GHP COF”) is a fund of alternative credit and distressed debt funds that is being raised and invested to pursue two specific investment themes: (1) the de-leveraging of European Banks, and (2) the potential for a distressed cycle in U.S. High Yield Credit. GHP COF will pursue complex liquid and illiquid credit opportunities in the U.S. and Europe.

Learn More

Monthly Archives: February 2018

MedMen Becomes The First Marijuana Unicorn

Posted on by Granite Hall Partners

It’s the first marijuana unicorn in the country. California basedMedMen recently received a $30 million investment from Captor Capital for 3% of the company placing the valuation of the currently private cannabis company at a billion dollars. Chief Executive Officer Adam Bierman said MedMen is expecting an additional private investment in February that will make the […]


MedReleaf Australia Commences Commercial Operations

Posted on by Granite Hall Partners

Indica Industries Pty Ltd, the partner of Canadian licensed producer MedReleaf (TSX: LEAF) (OTC: MEDFF) that is operating as MedReleaf Australia, has commenced commercial operations. The company, which received its cultivation and production license in November, will be initially importing oils and capsules that are available for delivery in the first quarter of 2018 to hospitals and pharmacies. […]


RISE Research and Constance Therapeutics Announce Comprehensive Strategic Partnership

Posted on by Granite Hall Partners

Toronto, Ontario–(Newsfile Corp. – January 30, 2018) – RISE Research Inc. (“RISE”) and Luminor Medical Technologies Inc. (CSE: LMT) (“Luminor”) are pleased to announce RISE’s comprehensive strategic partnership with Constance Therapeutics (“CT”), an established San Francisco-based developer and manufacturer of premium medical cannabis extract products for physician and patient use in California. The partnership includes […]


Blackstone’s fourth-quarter profit jumps 5% on private-equity gains

Posted on by Granite Hall Partners

Blackstone the world’s largest manager of alternative assets, said on Thursday a key measure of its earnings rose by 5 percent, helped by large gains in its private-equity unit and a strong performance by its real estate, credit, and hedge fund businesses. Blackstone followed its peer Apollo Global Management in reporting strong appreciation in its buyout funds […]